RxDoctor Payments Data

Gaurav Sharma, MD

Surgery · Moorestown, NJNPI 1710276605

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $36,963 of the $51,048 with a category attached, or 72.4%. Covidien LP accounts for 80.6% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2020 at $33,639 and has fallen 98.8% since, to $414 in 2025. Among surgery clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$51,048in general payments, 2019–2025

Across 70 payments — averaging $729.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Covidien LP$41K
  • Intuitive Surgical$8K
  • Standard Bariatrics, Inc.$345
  • Baxter Healthcare$321
  • Novo Nordisk$197
  • Lilly USA, LLC$181
  • plus $370 from 10 others

What the payments were for

  • Consulting fees$36,96372%
  • Travel & lodging$4,2128%
  • Food & beverage$1,8734%
  • Education$8,00016%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$51,048 in reported general payments places this provider in the 95th percentile of 593 surgery providers in New Jersey.

See all surgery providers in New Jersey

Medicare billing

Part B allowed, 2024
$31,147
Medicare patients
86
Services billed
141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
WegovySemaglutide24$34,631
Pantoprazole Sodium35$243
Omeprazole20$238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskWegovy$197$34,63124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 593 surgery providers in New Jersey.

Other surgery in Moorestown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →